Market Overview

BioPharmX Says Phase 2b Trial Met Endpoints


Biopharmx Corp (NYSE: BPMX) shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was well tolerated.

This news pushed BioPharmX from 88 cents to $1.27 per share, but the stock traded around 84 cents at time of publication.

Related Links:

Akorn Receives FDA Warning Letter, Says It's Committed To Resolving Issues

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Posted-In: Biotech News Penny Stocks Markets General


Related Articles (BPMX)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

York Water CEO Set To Retire

Obalon Ticks Higher Amid Patent Abstract For Intragastric Device